Toron Capital Markets Decreased Its Vermilion Energy (VET) Stake; Peregrine Pharmaceuticals Has 1.33 Sentiment

July 6, 2017 - By Michael Collier

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $189.43 million. The Firm operates through two divisions: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party clients on a fee-for-service basis while also supporting its internal drug development efforts. It currently has negative earnings. Bavituximab is its lead immunotherapy candidate.

Toron Capital Markets Inc decreased Vermilion Energy Inc (VET) stake by 13.02% reported in 2016Q4 SEC filing. Toron Capital Markets Inc sold 160,790 shares as Vermilion Energy Inc (VET)’s stock declined 12.81%. The Toron Capital Markets Inc holds 1.07 million shares with $45.18M value, down from 1.23 million last quarter. Vermilion Energy Inc now has $3.86 billion valuation. The stock decreased 3.86% or $1.25 during the last trading session, reaching $31.15. About shares traded. Vermilion Energy Inc (NYSE:VET) has risen 5.95% since July 6, 2016 and is uptrending. It has underperformed by 10.75% the S&P500.

Among 2 analysts covering Vermilion Energy (NYSE:VET), 0 have Buy rating, 1 Sell and 1 Hold. Therefore 0 are positive. Vermilion Energy had 2 analyst reports since August 11, 2015 according to SRatingsIntel. The stock of Vermilion Energy Inc (NYSE:VET) has “Hold” rating given on Tuesday, August 11 by Desjardins Securities. The firm earned “Sell” rating on Thursday, November 5 by Goldman Sachs.

Toron Capital Markets Inc increased Ross Stores Inc (NASDAQ:ROST) stake by 8,807 shares to 216,180 valued at $14.18 million in 2016Q4. It also upped Goldcorp Inc New (NYSE:GG) stake by 197,818 shares and now owns 2.82M shares. Us Bancorp Del (NYSE:USB) was raised too.

Analysts await Vermilion Energy Inc (NYSE:VET) to report earnings on July, 26 after the close.

Analysts await Peregrine Pharmaceuticals (NASDAQ:PPHM) to report earnings on July, 13. They expect $-0.01 earnings per share, up 80.00% or $0.04 from last year’s $-0.05 per share. After $-0.04 actual earnings per share reported by Peregrine Pharmaceuticals for the previous quarter, Wall Street now forecasts -75.00% EPS growth.

Nine Chapters Capital Management Llc holds 0.1% of its portfolio in Peregrine Pharmaceuticals for 184,700 shares. Kennedy Capital Management Inc. owns 7.58 million shares or 0.04% of their US portfolio. Moreover, Eqis Capital Management Inc. has 0.02% invested in the company for 1.16 million shares. The California-based Sterling Global Strategies Llc has invested 0.02% in the stock. Baxter Bros Inc, a Connecticut-based fund reported 139,100 shares.